Blog

McBride plc (LSE:MCB) said full-year adjusted operating profit for the year ending June 2026 is expected to be in line with both market expectations and the previous two financial years, as recent improvements in trading performance continue to gain traction. While first-half adjusted operating profit is set to come in slightly below the exceptionally strong comparative period last year, management expects a stronger second half, supported by a pipeline of confirmed new business launches that are scheduled to come on stream.

For the six months to 31 December 2025, group revenue increased 0.8% at reported rates, with volumes up 0.4%. Demand for private label products remained robust, helping to sustain stable profitability through a combination of product engineering, operational efficiencies and tight control of overheads. Net debt rose to £120.6 million, equivalent to around 1.4 times trailing 12-month EBITDA, following £12.9 million returned to shareholders via dividends, a share buyback and Employee Benefit Trust purchases designed to limit future equity dilution. The company is due to report its half-year results on 24 February 2026.

Looking ahead, McBride expects the combination of steady private label demand, confirmed contract wins and ongoing efficiency initiatives to support profit growth into 2027 and 2028. Although financial performance still has scope for further improvement, recent strategic progress and a supportive valuation backdrop provide a constructive outlook.

More about McBride

McBride plc is a leading European manufacturer and supplier of private label and contract-manufactured products for domestic household and professional cleaning and hygiene markets. The group serves major retailers and customers across its core European geographies, where private label demand remains strong and market share is at or near recent highs across its five largest markets.

Staffline Group (LSE:STAF) reported a strong full-year performance for 2025 following its strategic shift to a pure-play recruitment model, with results coming in well ahead of market expectations. Revenue increased 11.5% to £1.11 billion, gross profit rose 10.6% to £78.3 million and operating profit jumped 28.3% to £12.7 million, reflecting improved execution and market share gains.

Growth was driven primarily by the group’s core UK blue-collar recruitment business, where it secured additional share and benefited from a major new logistics partnership. This contract added around 1,800 temporary workers and contributed to peak trading hours reaching a five-year high. In Ireland, permanent recruitment fees grew at a double-digit rate, while the group also made profitable progress in recruitment process outsourcing and managed services. Net cash declined over the period due to planned working capital investment and the continuation of a £7.5 million share buyback programme, but management highlighted stronger profit conversion and a robust balance sheet.

Looking ahead, Staffline believes its streamlined focus, strong new business pipeline and the fragmented nature of the recruitment market position it well to benefit from ongoing customer consolidation of labour suppliers. While profitability remains an area to continue improving, recent contract momentum and operational progress provide a supportive backdrop for further growth.

More about Staffline

Staffline Group is one of the UK’s leading recruitment companies, operating through two main divisions: Recruitment GB and Recruitment Ireland. Recruitment GB supplies flexible blue-collar labour, providing around 40,000 workers per day across more than 500 client sites in sectors such as supermarkets, food processing, logistics, driving, manufacturing and beverages. Recruitment Ireland delivers end-to-end recruitment solutions, supplying around 4,500 staff per day and offering RPO, managed services, and temporary and permanent staffing across public and private sectors, with a particular emphasis on health, social care and public services across the island of Ireland.

4imprint Group plc (LSE:FOUR) delivered a resilient trading performance in 2025, reporting unaudited revenue of $1.35 billion and profit before tax of at least $149 million, both ahead of the top end of market expectations. The result was achieved against a volatile macroeconomic backdrop, highlighting the strength of the group’s operating model.

Order volumes edged lower during the year, largely reflecting a 12% decline in orders from new customers. This was offset by stable ordering behaviour from existing clients, a 1% uplift in average order value and a robust gross margin of around 32%. As a result, 4imprint maintained a double-digit operating margin and generated strong cash flows, leaving the balance sheet well funded as the company enters 2026. Management said this financial strength positions the business to manage ongoing uncertainty while remaining well placed to capture future growth opportunities.

The group is scheduled to publish its audited full-year results for the year ended 27 December 2025 on 11 March 2026, alongside a webcast for analysts and investors.

More about 4imprint

4imprint Group plc is a leading international direct marketer of promotional products, supplying branded merchandise to businesses and organisations for marketing and corporate identity purposes. The group is primarily focused on high-volume markets in North America and operates a direct-to-customer model, supported by a flexible marketing approach designed to drive repeat ordering and strong customer retention.

Treatt plc (LSE:TET) reported a challenging full-year performance for the year ended 30 September 2025, as softer market conditions weighed heavily on results. Revenue declined 11.8% to £132.5 million, while profit before tax and exceptional items fell 44.4% to £10.3 million, reflecting weaker US consumer demand, tariff-related uncertainty and persistently high citrus input costs.

Margin pressure was evident across the business, with adjusted EBITDA down by around a third. Earnings per share and dividends were reduced, and net debt increased to £5.9 million, partly due to a £5 million share buyback completed during the year. Despite these headwinds, management emphasised continued discipline around cash generation and reiterated its commitment to maintaining a progressive dividend policy over the longer term.

Strategically, the group highlighted a number of operational positives. These included a significant commercial win for its sugar reduction platform, investment in expanded sales teams in Germany and France, and the opening of a new commercial and innovation centre in Shanghai. Treatt also extended its reach in Asia through a distribution agreement in South East Asia with IMCD. After the year end, the company entered into a relationship agreement with major shareholder Döhler, following the lapse of a competing private equity-backed takeover approach. The board believes this relationship, alongside the group’s underutilised but well-invested manufacturing capacity, could support a return to profit growth, while noting the need to manage potential conflicts given Döhler’s position as both a key customer and significant shareholder.

More about Treatt plc

Treatt plc is a global, independent manufacturer and supplier of natural extracts and ingredients to the flavour, fragrance and multinational consumer goods industries, with a strong focus on beverages. Known for its technical expertise and deep understanding of ingredient sourcing and market dynamics, the group operates manufacturing facilities in the UK and the US and employs around 350 people across Europe, North America and Asia. Treatt leverages its international footprint to deliver integrated, value-added solutions to customers worldwide.

Avacta Group plc (LSE:AVCT) reported solid operational and research progress during 2025, underpinned by encouraging clinical data and continued advancement of its proprietary tumour-activated drug delivery platform. Updated results from Phase 1b expansion cohorts of faridoxorubicin (AVA6000) showed supportive efficacy and safety signals in salivary gland cancer, while patient enrolment continued to help refine trial design ahead of later-stage studies.

The company also moved its second pre|CISION® programme, FAP-Exd (AVA6103), further forward, supported by positive pharmacology data. A Phase 1 trial is scheduled to begin in early 2026 across multiple specialist oncology centres in the US, targeting four AI-selected tumour types. Alongside programme execution, Avacta introduced additional platform innovations, including a sustained-release mechanism and a dual-payload delivery technology, aimed at broadening the potential applications of its platform.

On the financial side, Avacta raised £22.5 million in equity during 2025 and finished the year with £16.9 million in cash and equivalents. This funding is expected to support operations into the third quarter of 2026, allowing the company to reach key data readouts for both AVA6000 and AVA6103. Management also confirmed that partnering discussions remain active, which could influence the structure, funding and risk profile of future pivotal trials and wider pipeline development.

More about Avacta Group plc

Avacta Group plc is a clinical-stage biopharmaceutical company focused on oncology, developing its proprietary pre|CISION® tumour-activated drug delivery platform. Its lead programmes, faridoxorubicin (AVA6000) and FAP-Exd (AVA6103), are designed to release chemotherapy agents directly within tumours at high concentrations while limiting systemic toxicity. The company targets difficult-to-treat solid cancers including salivary gland, pancreatic, gastric, small cell lung and cervical cancers, with a strategy centred on platform expansion, intellectual property development and collaboration with global pharmaceutical partners.

Kier Group plc (LSE:KIE) said trading for the six months to 31 December 2025 was in line with expectations, underpinned by a record order book of £11.6 billion. The group noted that around 94% of forecast FY26 revenue is already secured, providing strong forward visibility.

Kier also marked a significant balance-sheet improvement, achieving an average month-end net cash position of approximately £15 million, compared with net debt at the same point last year. The company expects to report a materially higher period-end net cash balance than in the prior year, highlighting the progress made in strengthening financial resilience. Recent contract awards included work under British Airways’ Better Buildings framework, Southern Water’s AMP8 programme, an extension at Hinkley Point C, major education schemes and the Government Property Agency’s hub in Darlington. Within property, the group secured planning consent for an industrial development in Manchester and completed a logistics project in Milton Keynes.

Strategically, Kier has merged its Transportation and Natural Resources, Nuclear & Networks operations into a single Infrastructure division, aiming to better capture opportunities arising from increased UK government infrastructure investment. The leadership team has also been reinforced with the appointment of Tom Hinton as chief financial officer and Martin Staehr as managing director of Construction, moves intended to support the group’s next phase of growth.

Overall, Kier’s outlook is supported by strong trading momentum, improved cash generation and a highly visible pipeline of work. While leverage remains an area of focus, recent operational and financial progress, alongside a reasonable valuation, provides a more constructive backdrop for the shares.

More about Kier Group plc

Kier Group plc is a leading UK infrastructure services, construction and property company, delivering design-and-build and project management solutions across sectors including transport, education, healthcare, justice, defence, water, energy, aviation and nuclear. The group applies specialist technical expertise and integrated delivery capabilities to complex projects for both public- and private-sector clients throughout the UK.

PetroTal Corp. (LSE:TAL) has published its 2026 budget and outlook, outlining a transition year that prioritises liquidity protection, tighter cost control and operational stability rather than near-term production growth. The board has approved capital expenditure of $80–90 million, targeting average production of 11,750–12,250 barrels of oil per day in 2026 while maintaining a minimum of $60 million in unrestricted cash.

The programme allocates around $45 million to drill two development wells at the Bretaña Norte oil field by the end of the year, alongside material spending on erosion control and critical infrastructure. As part of its cost and risk management strategy, PetroTal plans to transition to a third-party drilling contractor and exit its Amazonia-1 rig lease, a move intended to reduce scheduling risk and better align costs with a lower level of activity. At a Brent oil price of $60, the company expects adjusted EBITDA of roughly $30 million, supported by reductions in operating expenditure and G&A.

All Bretaña crude will be marketed via the Brazil export route during the period, while the company works toward restoring production capacity to above 20,000 barrels per day from 2027. Future investments in water handling and infrastructure expansion are expected to be funded from internally generated cash flow, reinforcing management’s emphasis on balance sheet resilience ahead of the next growth phase.

More about PetroTal Corp

PetroTal Corp. is a publicly listed oil and gas development and production company headquartered in Calgary and Houston, with a sole focus on Peruvian oil assets. Its core operation is a 100% working interest in the Bretaña Norte field in Block 95, where production began in 2018 and which has since become Peru’s largest crude oil producing asset. The company is led by a management team with deep experience in the Peruvian energy sector and places strong emphasis on cost-efficient development and responsible, community-focused operations.

Creo Medical Group (LSE:CREO) delivered a strong performance in FY25, with revenue increasing by 50% to £6.0 million alongside a sharp improvement in cost efficiency. Underlying operating expenses fell 20% to £18.4 million, helping to cut the underlying operating loss by more than 40% to £13.3 million. The group ended the year with a cash balance of £12.4 million.

Revenue growth was driven by continued clinical adoption and higher utilisation across Creo’s core product portfolio. Use of the Speedboat Notch device increased in advanced gastrointestinal procedures, while the newly launched SpydrBlade Flex received encouraging early feedback following its introduction in the US, UK and EU. Progress was also made within the MicroBlate ablation portfolio, supported by commercial sales and limited market releases linked to ongoing clinical studies. Management highlighted confidence in further sequential revenue growth and improving operational leverage in FY26, positioning the business towards more sustainable cash flows as scale builds.

Looking ahead, Creo Medical’s outlook reflects a mix of improving operational momentum and ongoing financial challenges. While the company remains loss-making and valuation metrics continue to reflect this, recent progress in cost control, product adoption and commercial execution provides a more constructive backdrop for future growth in the minimally invasive endoscopic oncology market.

More about Creo Medical

Creo Medical Group is a UK-based medical device company focused on minimally invasive electrosurgical technologies for use in endoscopic procedures for pre-cancer and cancer patients. Its proprietary CROMA platform, powered by Kamaptive technology, combines bipolar radiofrequency and microwave energy to enable tissue resection, dissection, coagulation and ablation. The group aims to provide clinicians with safer, more precise and cost-effective alternatives to conventional surgical techniques, particularly in gastrointestinal and related applications.

Ibstock (LSE:IBST) delivered a resilient full-year performance in 2025 despite a tougher trading backdrop in the second half, with revenue increasing 2% to approximately £372 million. EBITDA and trading cash flow were in line with management guidance, while net debt stayed broadly stable at around £120 million, supported by roughly £30 million of proceeds from disposals of non-core assets.

The group has now largely completed its major capital investment programme at the Atlas and Nostell plants and has taken decisive actions to align costs and capacity with market conditions. These measures included headcount reductions, the disposal of surplus land and the sale of the smaller Forticrete roofing business. Looking ahead, Ibstock plans to actively manage production levels and inventories in response to a subdued housing and repair, maintenance and improvement market. Management has indicated it is prepared to accept some margin pressure in 2026 in order to prioritise cash generation and protect balance sheet strength, which it believes will provide flexibility for future growth initiatives and potential capital returns as demand recovers.

Overall, the company’s outlook reflects a balance between financial resilience and ongoing market challenges. Recent corporate actions have strengthened financial flexibility and strategic positioning, although slower revenue momentum and free cash flow generation remain key areas for investors to monitor, particularly given valuation considerations.

More about Ibstock

Ibstock Plc is a leading UK manufacturer of building products and solutions, operating through two main divisions. Ibstock Clay is the UK’s largest clay brick producer by volume, with 15 factories, associated quarries, and a masonry and prefabricated components operation. Ibstock Concrete supplies concrete walling, flooring, fencing, lintels, and rail and infrastructure products from 11 sites. These core businesses are supported by Ibstock Futures, which focuses on sustainable solutions and Modern Methods of Construction, underpinned by an ESG 2030 strategy targeting a 40% reduction in carbon emissions by 2030 and net zero operations by 2040.